Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

Raltegravir is the preferred INSTI for for treatment of antiretroviral-naïve pregnant women in the US Perinatal Guidelines, alongside Dolutegravir, and for late pregnancy. There are relatively limited information available on its use during early pregnancy, particularly the peri-conception period. The aim of the study is to assess "real-world" maternal, fetal and newborn outcomes following RAL use during pregnancy through pooled analysis of individual patient data from observational studies participating in the European Pregnancy and Paediatric Infections Cohort Collaboration.

Start Date20 Feb 2023

Sponsor / Collaborator-

NCT03954327

/ CompletedPhase 2IIT

Randomized Controlled Trail (RCT) of Emtricitabine, Tenofovir Disoproxil and Raltegravir for Patients With Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid (UDCA)

Placebo Controlled, double-blind randomized controlled trial (RCT) with 12 months Tenofovir Disoproxil and Raltegravir for primary biliary cholangitis (PBC) patients unresponsive to Ursodeoxycholic Acid (UDCA). Placebo patients will be offered 12 months open label therapy at unblinding. All patients will be offered an additional 12 months open label therapy. Observational, open label study will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

Start Date01 Mar 2021

Sponsor / Collaborator

University of Alberta

[+1]

NCT04258475

/ Unknown statusPhase 4IIT

The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir.

The purpose of this study is to measure change in raltegravir serum pharmacokinetics in steady state, when co-administered with calcium carbonate formulated as antacid.

Start Date09 Dec 2020

Sponsor / Collaborator

Ottawa Hospital Research Institute

100 Clinical Results associated with Raltegravir Potassium

100 Translational Medicine associated with Raltegravir Potassium

100 Patents (Medical) associated with Raltegravir Potassium

3,028

Literatures (Medical) associated with Raltegravir Potassium

01 Oct 2026·VIROLOGY

Generation and evaluation of an EcoHIV mouse model to study HIV-1 integration and expression

Article

Author: Ren, Siyao ; Liu, Jiarui ; Yang, Zihao ; Ma, Yige ; Wei, Wanrong ; Ma, Yan ; Liu, Yue ; Zhou, Ying ; Gu, Chaojiang ; Xia, Xuejiao ; Wang, Changjun ; Gao, Yang ; Li, Jiezhen ; Yu, Lei

Antiretroviral therapy suppresses HIV replication but does not purge the latent reservoirs, which remains a major barrier to cure. There is an urgent need to establish a reservoir in a mouse model for investigation of viral replication and clearance. We established an EcoHIV infection model in conventional mice by replacing HIV-1 gp120 protein with an ecotropic murine leukemia virus envelope to enable entry via the murine mCAT-1 receptor. EcoHIV can infect immunocompetent mice and multiple mutant mouse strains and replicate in CD4⁺ T cells, macrophages, and immune cells in the brain. We created and systematically validated a nested qPCR for quantitation of HIV-1/EcoHIV integration events, and we found that viral genomic integration was significantly suppressed by HIV-1 integrase inhibitors such as Raltegravir. The immunofluorescence staining indicated EcoHIV can be efficiently transmitted from infected CD4 + T cells to macrophages in vitro and EcoHIV expression was effectively inhibited by Abacavir and Raltegravir. Importantly, BLI data demonstrate that EcoHIV establishes latent reservoirs -like state in mice which can be reactivated by LRA treatment. Altogether, our model provides a valuable platform for the controlled study of HIV entry, integration, transmission, latency within tissue-resident compartments under ART and for the preclinical evaluation of latency-reversing and curative strategies.

01 Aug 2026·BIOMEDICINE & PHARMACOTHERAPY

Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress

Article

Author: Della Torre, Sara ; Sfogliarini, Chiara ; Rizzo, Angela Maria ; Vegeto, Elisabetta ; Allegretti, Marcello ; Bernardinelli, Camilla ; Tran, Lien Hong ; Locati, Massimo ; Cesta, Maria Candida ; Corsetto, Paola Antonia ; Cattani, Franca

Macrophages are key effectors of innate immune responses and infection control, relying on Toll-like receptors (TLRs) to sense pathogens and adopt immunometabolic anti-infective phenotypes. Raloxifene (RAL) and tamoxifen (TAM) are selective estrogen receptor modulators (SERMs) known to reprogram macrophage inflammatory responses via estrogen receptor-independent mechanisms, including NRF2 activation. Although drug repurposing approaches have highlighted anti-infective properties of these compounds, supporting host-directed mechanisms, the upstream targets and immune consequences of RAL and TAM in macrophages remain undefined. Here, we investigated the biological relevance and molecular determinants of SERM-mediated immune activity in TLR-activated macrophages. Our results show that RAL and TAM modulate inflammatory cytokine expression induced by TLR7/8, TLR4, and TLR2 stimulation. Specifically, these SERMs enhance IL 1β maturation, despite reducing proIl1b mRNA levels, and increase TNF α production, while restraining IL 6 expression. Notably, IL 6 repression is more pronounced with RAL and correlates with sustained NRF2 pathway engagement, suggesting a drug-specific immunoregulatory profile. Furthermore, RAL and TAM influence cytokine regulation through cholesterol-pathway remodeling consistent with AEBS inhibition, which was associated with PI3K-NRF2 activation and NRF2-related immunometabolic adaptation. In parallel, RAL and TAM promote lysosomal perturbations, leading to the regulation of proIl1b and Tnfa mRNA levels and to cathepsin B-associated caspase-1 activation and IL1β production. Cathepsin B inhibition further enhances NRF2-target gene responses, suggesting functional crosstalk between lysosomal and NRF2-associated pathways. Overall, these findings indicate that RAL and TAM elicit an integrated immunometabolic reshaping of macrophage inflammatory phenotypes, through cholesterol-pathway remodeling and lysosomal stress, supporting SERMs as host-directed chemotherapeutic agents.

01 Jun 2026·VIRUS GENES

Evolution and emergence of the integrase inhibitor 231 insertion resistance mutation in an HIV-2 strain isolated in central Portugal

Article

Author: Duque, Vítor ; Carmo, Anália ; Mendes, Alexandra ; Pereira-Vaz, João ; Rodrigues, Fernando ; Alves, Ana ; Morais, Célia

Limited in vivo data are available regarding the recently described integrase (IN) codon 231 insertion mutation in Human immunodeficiency virus 2 (HIV-2) because this new resistance pathway to integrase strand transfer inhibitors (INSTIs) has only been found in very few clinical isolates. This study reports the emergence of the IN codon 231 insertion resistance mutation in an HIV-2 strain isolated from a person with HIV-2 (PWH-2) undergoing antiretroviral treatment with a raltegravir (RAL) containing regimen, in central Portugal. Longitudinal nucleotide sequences of the IN coding region (codons 1-293) obtained prior to and at the time of treatment failure were retrospectively analyzed for genotypic resistance to antiretroviral drugs. The 5 amino acid insertion mutation between codons 231 and 232 was detected in the IN C-terminal domain of an HIV-2 group A strain 156 months after initiation of a RAL-containing regimen. The insertion mutation was not present before exposure to RAL. No other resistance-associated mutation to INSTIs was detected at the time of treatment failure. The insertion profile found, GYRGK, was similar to those previously described, and clearly emerged under the selective pressure of RAL, which is in agreement with previously reported evidence of a significant correlation between treatment failure to INSTIs and the emergence of R231_insert containing viruses. Our findings expand the available genotypic data regarding this resistance pathway and should help to improve HIV-2 resistance interpretation algorithms.

News (Medical) associated with Raltegravir Potassium

22 Apr 2026

·www.biospace.com

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”),” today announced the completion of enrollment in its Phase 2 clinical study (ClinicalTrials.gov Identifier: NCT06699836 ) evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC), also known as CLOVER – C CR5-targeting L eronlimab With O ral Chemotherapy and V EGF-inhibitor E nriched R egimen. The open-label, randomized, two-arm, multi-center study is evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients who have progressed following prior standard therapies. With enrollment now complete, CytoDyn will advance the study through treatment and follow-up, with resulting data expected to inform the program’s development strategy and potential next steps. “Completing enrollment in this Phase 2 study marks an important milestone for CytoDyn and for the continued development of leronlimab in oncology,” said Dr. Jacob Lalezari, Chief Executive Officer of CytoDyn. “We are grateful to the patients, investigators, and clinical sites whose commitment made completion of enrollment possible and look forward to evaluating the study results.” “CLOVER is designed to prospectively assess the activity of leronlimab in combination with an established regimen in a difficult to treat and highly refractory patient population with microsatellite stable (MSS) metastatic colorectal cancer, ” said Pashtoon M. Kasi, M.D., M.S., Principal Investigator of the study and Medical Director of GI Oncology, City of Hope Orange County, Irvine, California. “With enrollment now complete, the study is well positioned to generate meaningful insights in this patient population with a high unmet need.” The CLOVER study builds on emerging clinical and translational findings from CytoDyn’s ongoing Phase 2 mCRC program, including data being presented at the AACR Annual Meeting 2026. Preliminary results demonstrated early signals of clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, including rapid reductions in circulating tumor DNA and modulation of immune-related markers. These findings support further evaluation of CCR5 inhibition as a strategy to enhance anti-tumor activity in metastatic colorectal cancer. Leronlimab is a monoclonal antibody targeting CCR5, a receptor involved in immune cell trafficking and tumor biology. By blocking CCR5, leronlimab may help modulate the tumor microenvironment and enhance the activity of existing therapies in difficult-to-treat cancers. CytoDyn plans to share topline data from the study as they become available. About the Phase 2 mCRC Study (NCT06699836) This Phase 2 clinical study is an open-label, randomized, two-arm, multi-center study evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC), also known as CLOVER – C CR5-targeting L eronlimab With O ral Chemotherapy and V EGF-inhibitor E nriched R egimen. Approximately 60 patients were enrolled and randomized 1:1 to receive either 350 mg or 700 mg of leronlimab in combination with standard-of-care therapy. Eligible participants are adults with histologically confirmed mCRC who have progressed following prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, where appropriate, anti-EGFR therapy. The primary endpoint of the study is objective response rate (ORR), as defined by RECIST v1.1 criteria. Secondary endpoints include safety and tolerability, duration of response, and overall survival. Patients will be followed for up to 12 months. About CytoDyn CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide. For more information, please visit and follow us on LinkedIn . Note Regarding Forward-Looking Statements This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law. Corporate Contact CytoDyn Inc. ir@cytodyn.com Media Contacts David Schull or Ignacio Guerrero-Ros, Ph.D. Russo Partners, LLC CytoDyn@russopartnersllc.com

Phase 2Clinical ResultAACR

10 Jun 2025

·www.biospace.com

Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision

iStock, Nuthawut Somsuk Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused five clinical trials. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline. Five clinical trials for Gilead’s investigational weekly HIV combo pill have been placed on hold by the FDA after a safety signal emerged. While the combo includes a version of Gilead’s lenacapavir, which is approved as Sunleca for twice-yearly treatment of people with multi-drug-resistant HIV and currently under FDA review for the prevention of HIV, Jefferies analysts said the pause will not affect the looming decision date. Gilead announced the clinical hold Tuesday morning, explaining in a release that two Phase II/III trials named WONDERS-1 and -2 had been paused, plus three Phase I studies. The combination therapy features the integrase strand transfer inhibitor GS-1720 and/or the capsid inhibitor GS-4182. While Gilead did not mention lenacapavir in the release, Jefferies analysts explained that GS-4182 is a pro-drug formulation of the investigational therapy, which is separately under review for HIV pre-exposure prophylaxis (PrEP). “While it might increase some investor uncertainty into the all-important June 19 PDUFA for [lenacapavir] for PrEP, we see no major read-through and expect an on-time and clean FDA approval,” Jefferies wrote on Tuesday morning. BMO Capital Markets agreed but said that Gilead’s shares could still face some pressure Tuesday as investors digest the news. The company’s stock declined 2% to $110.75 as of 10:50 a.m. ET. Gilead said that the hold was placed after decreases in CD4+ T cell and absolute lymphocyte counts were identified in a subset of patients who received both drugs. This can be a signal of a weakened immune system in patients with HIV. The Phase II/III WONDERS-1 trial is comparing the combo with Gilead’s approved HIV medicine Biktarvy in people with HIV who are taking medication to suppress the virus. The Phase II/III WONDERS-2 study similarly features Biktarvy as the comparator but has enrolled patients with HIV who are treatment-naive. The company underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold. Gilead also stressed that the hold does not impact any other assets in its HIV pipeline. Jefferies agreed with this assessment, noting that had the FDA been concerned, it would have stalled more of Gilead’s formulations and integrase inhibitors currently under development. Any Day Now Gilead is seeking approval of lenacapavir as a twice-yearly injection for PrEP for HIV. The FDA’s decision, due June 19, has been eagerly anticipated by analysts, patients and Gilead, which is gearing up for a massive launch. The company is looking to the drug to build on its HIV empire, which is anchored by Biktarvy—a drug that recorded sales of $13.4 billion in 2024. BMO predicts peak sales of $6.5 billion for the PrEP indication. More broadly, Gilead is aiming to launch nine new HIV drugs by 2033. Gilead backed lenacapavir’s latest application with data from the Phase III PURPOSE 1 and PURPOSE 2 studies. PURPOSE 1, which focused on cisgender women, demonstrated 100% efficacy in preventing HIV infection. PURPOSE 2 enrolled a more diverse population of cisgender men, transgender men, transgender women and nonbinary individuals who have sex with partners assigned male at birth. Results showed that twice-yearly lenacapavir cut HIV incidence by 96% . Jefferies said this indication is very different from what the combo has been aimed at addressing in the now-stalled trials. It’s also unclear if the lenacapavir pro-drug is even the issue at this point. Other companies in the HIV space have had similar safety signals arise. Merck, for example, had trials of Isentress, launched in 2007, placed on hold by the FDA after CD4 T cell count reductions were observed. A combo of Isentress and Gilead’s lenacapavir for HIV treatment was also placed on hold several years ago but was ultimately released in 2022 using lower doses of Merck’s drug. Altogether, Jefferies is not too worried about the clinical hold. The firm places more weight on Phase I data for lenacapavir in combination with the injectable integrase inhibitors GS-1219 and GS-3242. Gilead intends to pick one of those medicines to move forward in a combo regimen with lenacapavir by the end of the year. The drugs are administered as a single dose at the first month and sixth month (Q6M). “This would be the real game changer and value proposition for Gilead if they are able to swap the $15B Biktarvy market onto long-acting Q6M injectable in the later half of the decade,” Jefferies wrote.

Phase 3Clinical ResultDrug ApprovalPhase 1Phase 2

09 May 2025

·pharma.economictimes.indiatimes.com

Lupin’s HIV generic gets FDA nod

Mumbai: Indian drugmaker Lupin Limited has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for a generic version of Raltegravir tablets . The approved product is bioequivalent to Isentress HD tablets, marketed by Merck Sharp & Dohme LLC, which recorded estimated annual sales of USD 34 million (around ₹290 crore) in the U.S. in FY25. Raltegravir is indicated, in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients and pediatric patients weighing at least 40 kg. According to the company, Lupin is the first-to-file for this product and is eligible for 180 days of generic drug exclusivity . The drug will be manufactured at Lupin’s Nagpur facility in India. Raltegravir Tablets USP, 600 mg (RLD: Isentress® HD), had an estimated annual sale of USD 34 million in the U.S. as per IQVIA MAT March 2025. By Online Bureau ,

Drug Approval

100 Deals associated with Raltegravir Potassium

External Link

KEGG	Wiki	ATC	Drug Bank
D07133	Raltegravir Potassium	J05AX08	DB06817

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Merck Sharp & Dohme Corp.	12 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	NDA/BLA	European Union	Viatris Ltd. (New Zealand)	-
Kidney Failure, Chronic	Phase 3	France	Merck Sharp & Dohme Corp.	01 Dec 2011
Hypertriglyceridemia	Phase 3	United States	Merck Sharp & Dohme Corp.	01 May 2009
AIDS-Related Opportunistic Infections	Phase 3	United States	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Canada	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	France	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Italy	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Poland	Merck Sharp & Dohme Corp.	01 Jul 2008
AIDS-Related Opportunistic Infections	Phase 3	Spain	Merck Sharp & Dohme Corp.	01 Jul 2008
HIV Seropositivity	Phase 3	-	Merck Sharp & Dohme Corp.	01 May 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03311945 (CTgov)	Phase 3	HIV Seropositivity	33	Lamivudine+raltegravir	dukbhyawhd = tmazxxuiea lwlyhnjotl (gjucjdnfrp, dffynlnpoo - xiyyhnhlyz) View more	-	18 Jul 2025
NCT03029689 (RAGTIME, CTgov)	Phase 3	HIV Infections	61	Current ART+raltegravir (Current ART + Raltegravir)	avwmzkqozm(uwspvchrkm) = gsyozuggsj xkwoniatmn (rjndatoylu, swbjwwwhlf - prjytxeqfs) View more	-	13 Apr 2025
				Current ART (Current ART + Placebo)	avwmzkqozm(uwspvchrkm) = lehhhvgows xkwoniatmn (rjndatoylu, oojzhqfnqy - vaozjhdaim) View more
NCT01854762 (PregnantHIV, CTgov)	Phase 2/3	Pregnancy \| HIV Infections	33	Raltegravir (Raltegravir)	btpvpbhirv = nhfxrchwwz oxjylwmayz (wwxotnnjrk, xpdcaibbha - yosvotmqrx) View more	-	15 Oct 2024
				Lopinavir/Ritonavir (Lopinavir/Ritonavir)	btpvpbhirv = yjqixemidq oxjylwmayz (wwxotnnjrk, stpboaxrzw - fsttaxtmcg) View more
NCT01641367 (ACTG A5288, Pubmed)	Phase 4	Third line	257	RAL	jzocqgsune(coslzqdraq) = vekzvmhdwf vpjedelogc (ungybnjtsy ) View more	-	01 Jun 2022
				DRV/r	iztdcwzefi(zkblowwvnh) = yfpcnrjvhl lsernqaycg (fqidqserlf )
NCT03374358 (Pubmed \| AIDS Patient Care STDS)	Phase 4	-	43	Switch to Raltegravir	lbrpakrxle(lkwhrdaaun) = eqzqmudwlp hldkqkxurm (wvxuygezsb ) View more	-	01 Sep 2021
				Continue unchanged antiretroviral therapy	mbdzvfuspz(mmijlfmrtg) = evaxvbtrpi lqbdlrnnqh (vooevsyied )
NCT01147107 (CTgov)	Phase 4	HIV Infections \| Hepatitis C, Chronic	80	raltegravir (Raltegravir Based Therapy)	hngfklzaun = aslubfuezg yxyhcasffi (xjuuibfoot, rlacbxzhcl - iwzrmcsimu) View more	-	13 Aug 2021
				Efavirenz (Efavirenz Based Therapy)	hngfklzaun = sxgkbieklx yxyhcasffi (xjuuibfoot, kbqvqiztyn - svrxvyngoy) View more
NCT03374358 (OBERAL, CTgov)	Phase 4	Metabolic Syndrome \| Fatty Liver \| HIV Seropositivity	45	raltegravir	vdjjdnruge(eipquosgji) = haegsdifsp pwquifhsgt (tcggxryklh, hmcqprwvvu - ognzauooub) View more	-	07 Jul 2021
NCT03205566 (R-PrEP, CTgov)	Phase 4	HIV Infections	38	Raltegravir (Raltegravir)	ayjtcilgbw(jpclckljyr) = bboxxmrbae llqhxqkuzs (onnjkddbmo, NA) View more	-	21 Feb 2021
				Raltegravir (Raltegravir During Combination Treatment)	ayjtcilgbw(jpclckljyr) = hdzispoxks llqhxqkuzs (onnjkddbmo, 231.40) View more
NCT01751568 (CTgov)	Phase 1/2	Tuberculosis \| Acquired Immunodeficiency Syndrome \| Pulmonary Tuberculosis ... View more	40	raltegravir (Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment)	rdzpbneplr = jmgiixrdsu kjovadnpcl (vdhwoznpqw, uixyhzddlv - wbntqedyzd) View more	-	21 Dec 2020
				raltegravir (Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment)	rdzpbneplr = fakllsyrtx kjovadnpcl (vdhwoznpqw, cwfqndpvsb - rymbkuqots) View more
NCT00752856 (CTgov)	Phase 2	HIV Infections	51	Kaletra+Isentress (1 - Kaletra + Isentress Taken Twice Daily)	sejlwlwmyz(sgzwcrafas) = vlghjvgkej bggbmxwvbm (dudzsiowbn, pzxounneuj - xibtggxpoi) View more	-	07 Jul 2020
				Atripla (2 - Atripla Taken Once Daily)	sejlwlwmyz(sgzwcrafas) = wvshktiejl bggbmxwvbm (dudzsiowbn, hbdjemerft - jnxgthvigv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis